Abstracts tagged "Women’s health"

Abstract Number: 0437 • ACR Convergence 2020
Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting
Jun Chu¹, Sarthak Gupta¹, Zerai Manna², Michael Davis¹, Yenealem Temesgen-Oyelakin¹, Elaine Poncio¹, Isabel Ochoa¹, Laura Lewandowski³, Mariana Kaplan⁴, Alan Decherney¹ and Sarfaraz Hasni², ¹National Institutes of Health, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³NIAMS, NIH, Rockville, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) predominantly affects women of childbearing age. Women affected by SLE have higher risk for infertility, miscarriages, and other pregnancy complications…
Abstract Number: 0538 • ACR Convergence 2020
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study
Madeline Peterson¹, Thomas O'Byrne¹, John Davis¹, Vanessa Kronzer¹, Lynne Peterson¹, Michael Weisman² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: The long-term safety of breast implants has been a debated topic; two recent studies have raised new concerns about their potential negative health effects…
Abstract Number: 0574 • ACR Convergence 2020
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Katherine Pryor¹, Chang Xu¹, Jamie Collins¹, Karen Costenbader² and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
Abstract Number: 0917 • ACR Convergence 2020
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Madelon Vonk¹, Mandy Avis², Kristell Marzin³, Salome Mack³, Sven Wind³ and Martina Gahlemann⁴, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Boehringer Ingelheim B.V., Alkmaar, The Netherlands, Alkmaar, Netherlands, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of SSc-ILD. As nintedanib may cause fetal harm, patients taking nintedanib…
Abstract Number: 0938 • ACR Convergence 2020
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Cecilia Nalli¹, Daniele Lini², Laura Andreoli², Francesca Crisafulli², Micaela Fredi², Maria Grazia Lazzaroni², Victoria Bitsadze³, Antonia Calligaro⁴, Valentina Canti⁵, Roberto Caporali⁶, Francesco Carubbi⁷, Cecilia Chighizola⁸, Paola Conigliaro⁹, Caterina De Carolis¹⁰, Teresa Del Ross⁴, Maria Favaro⁴, Maria Gerosa¹¹, Annamaria Iuliano¹², Jamilya Khizroeva³, Alexander Makatsariya³, Pierlugi Meroni¹³, Marta Mosca¹⁴, Melissa Padovan¹⁵, Roberto Perricone⁹, Patrizia Rovere-Querini¹⁶, Gian Domenico Sebastiani¹², Chiara Tani¹⁴, Marta Tonello⁴, Dina Zucchi¹⁴, Franco Franceschini¹⁷ and Angela Tincani², ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Department of Obstetrics and Gynecology of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁴Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy, ⁵Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁸Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Experimental Laboratory of Immunorheumatological Researches, Istituto Auxologico Italiano, Milan, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹⁰Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹¹Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan, Italy, ¹²Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹³Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵UO e Sezione di Reumatologia, Dipartimento di Scienze Mediche, Universita' degli Studi di Ferrara, Ferrara, Italy, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: The role of complement in the aPL related pathology has been widely studied in animal models. aPL can induce fetal loss in experimental animals but…
Abstract Number: 1006 • ACR Convergence 2020
Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort
Carine Salliot¹, Yann Nguyen², Amandine Gelot³, Xavier Mariette⁴, Marie-Christine Boutron-Ruault³ and Raphaèle Seror⁵, ¹CHR orleans, Orleans, France, ²1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ³Institut Gustave Roussy, Villejuif, France, ⁴Paris-Sud University, Rueil-Malmaison, France, ⁵Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France
Background/Purpose: The involvement of female hormones in the pathogenesis of Rheumatoid Arthritis (RA) is supported by numerous observations: a female predominance, an increased incidence in…
Abstract Number: 1257 • ACR Convergence 2020
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Sofia Gernaat¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Stanford Medicine, Stanford, CA, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1621 • ACR Convergence 2020
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
Mehret Birru Talabi¹, Kwonho Jeong¹, Kaleab Abebe¹, Megan Clowse², Robyn Domsic³ and Sonya Borrero¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Duke University, Chapel Hill, NC, ³University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…
Abstract Number: 2280 • 2019 ACR/ARP Annual Meeting
Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention
Katherine Pryor¹, Bill Albert ², Susan Ritter ³, Laura Tarter ³, Jonathan Coblyn ³, Bonnie Bermas ⁴, Caryn Dutton ³, Lydia Pace ³, Elizabeth Janiak ³ and Candace Feldman ⁵, ¹Brigham and Women's Hospital, Brookline, ²Power to Decide, Washington, DC, ³Brigham and Women's Hospital, Boston, ⁴UT Southwestern, Dallas, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Reproductive health intention screening is critical in women with systemic rheumatic diseases, as both disease activity and medication use can impact pregnancy outcomes. However,…
Abstract Number: 2289 • 2019 ACR/ARP Annual Meeting
Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells
Zejun Zhou ¹, Gary Gilkeson ², Diane Kamen ³, Jim Oates ⁴ and Wei Jiang⁴, ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴Medical University of South Carolina, Charleston
Background/Purpose: Progesterone plays a protective role in preventing inflammation and preterm delivery during pregnancy. However, the mechanism involved is unknown. Microbial product translocation from a…
Abstract Number: 1934 • 2014 ACR/ARHP Annual Meeting
Examing Why Minority Women Are Risk Averse : A Qualitative Study
Sonal Bhalla¹, Kristin Mattocks² and Liana Fraenkel³, ¹Yale-New Haven Hospital, New Haven, CT, ²VA Central Western Massachusetts Healthcare System, University of Massachusetts Medical School, Leeds, MA, ³Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT
Background/Purpose: Prior research has shown that when making choices about the risks and benefits of medications, women from minority ethnic groups tend to be more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].